BIOVIE INC. (BIVI): Nasdaq/NYSE listing notice — BioVie receives Nasdaq delisting notice; has 180 days to regain compliance

BIOVIE INC.

Nasdaq notified BioVie that its stock closed below $1.00 for 30 consecutive business days.
Company granted 180-day grace period until October 15, 2024 to meet minimum bid price.
Compliance requires closing bid price of at least $1.00 for 10 consecutive business days.
Eligible for second 180-day extension if other Nasdaq initial listing standards are met.
Currently has stockholders' equity of at least $5 million; no assurance of regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

BIOVIE INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

April 18, 2024, BioVie Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price for the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Nasdaq Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180 calendar day grace period, or until October 15, 2024, to regain compliance with the minimum bid price requirement. The continued listing standard will

View on SEC.gov

90 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BIOVIE INC. filing history →

Source: SEC EDGAR

accession 0001520138-24-000179

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.